In 17 heavily pretreated NSCLC EGFR mutant (EGFR mut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses ...

The FDA's so-called complete response letter was related to observations as part of a standard pre-approval inspection at a ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

Genetic Signature May Predict Response to Immunotherapy for Non-Small Cell Lung Cancer Feb. 23, 2024 — A new study identified a set of 140 genes that may help predict enhanced disease-free ...